share_log

Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $8

Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $8

Canaccord Genuity維持對Bioventus的買入,將目標股價上調至8美元
Benzinga ·  2024/05/09 00:35

Canaccord Genuity analyst William Plovanic maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $7 to $8.

Canaccord Genuity分析師威廉·普洛瓦尼奇維持Bioventus(納斯達克股票代碼:BVS)的買入並將目標股價從7美元上調至8美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論